In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy.

ABSTRACT:

Introduction

Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase is considered a safe option if suitable molecular monitoring is available. However, the question arises as to which factors can contribute to the maintenance of TFR, and immunologic surveillance of the remaining leukemic cells is believed to be one of them. Argentina Stop Trial is an open-label, single-arm, multicenter trial assessing TFR after tyrosine kinase inhibitors interruption, that after more than 4 years showed a successful TFR rate of 63%.

Methods

In this context, we set up an immunological study by flow cytometry in order to analyze specific NK cell subsets from peripheral blood patient samples both at the time of discontinuation as well as during the subsequent

SUBMITTER: Sanchez MB 

PROVIDER: S-EPMC10561287 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature